Status:
UNKNOWN
Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
Lead Sponsor:
Vilnius University
Conditions:
Hematologic Neoplasms
COVID-19 Vaccines
Eligibility:
All Genders
12+ years
Brief Summary
The study will evaluate the immunogenicity, safety and efficacy of vaccines against severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) in oncohematological patient population and compare th...
Detailed Description
The study will evaluate the immunogenicity, safety and efficacy of vaccines against SARS-CoV-2 in oncohematological patient population and compare the results with patients without prior oncohematolog...
Eligibility Criteria
Inclusion
- Inclusion criteria for oncohematological patients
- \>/= 12 years of age.
- Prior diagnosis of oncohematological disease.
- The patient has signed an informed consent form.
- The patient was vaccinated with SARS-CoV-2 vaccine.
- Inclusion criteria for healthy individuals
- \>/= 12 years of age.
- Patients without prior diagnosis of oncohematological disease.
- The patient has signed an informed consent form.
- The patient was vaccinated with SARS-CoV-2 vaccine.
- Exclusion criteria No exclusion criteria will be applied.
Exclusion
Key Trial Info
Start Date :
March 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
3270 Patients enrolled
Trial Details
Trial ID
NCT04871165
Start Date
March 24 2021
End Date
March 1 2024
Last Update
January 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vilnius University Hospital Santaros Klinikos
Vilnius, Lithuania, LT-08661